BioMarin Pharmaceutical's Achondroplasia Treatment Gets FDA Approval for All Pediatric Patients
By Sabela Ojea
BioMarin Pharmaceutical said the Food and Drug Administration has approved its new drug application to treat all pediatric patients with a growth condition.
The biotechnology company on Friday said its Voxzogo treatment is aimed at increasing linear growth and has been approved based on an improvement in annualized growth velocity.
The medication had previously been indicated for achondroplasia patients who were 5 years of age and older.
Voxzogo is currently approved in Europe for children with achondroplasi who are at least 2 years old.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 20, 2023 16:39 ET (20:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Broadcom Stock a Buy, a Sell, or Fairly Valued?
-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Micron Stock Soars With the AI Boom—Is It a Buy or a Sell?
-
With a 4% Dividend Yield and Significant Growth Potential, This Stock Is a Buy
-
10 Stocks the Best Fund Managers Have Been Buying
-
GE Aerospace Stock Has Skyrocketed 86%. Is It a Buy?
-
2 Undervalued Dividend Stocks the Best Managers Are Buying
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains